title: Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
abstract: BACKGROUND
  A prospective randomised study involving 810 elderly patients was conducted in an attempt to compare alternating chemotherapy with conventional first-line chemotherapy in aggressive non-Hodgkin's lymphoma in order to improve prognosis with an acceptable toxicity for elderly patients.
  
  
  METHODS
  Patients included were 55-69 years old and had at least one adverse prognostic factor. Patients were treated either with ACVBP followed by consolidation (n = 396) or with an alternating regimen (n = 414). This regimen was an association of active drugs in NHL relapsing patients, alternating VIMMM with ACVBP for induction and alternation of VIM and ACVM in consolidation. Eight hundred and sixty-six patients were randomised. After histological review, 810 patients met the inclusion criteria: 396 in arm A, 414 in arm B.
  
  
  RESULTS
  The complete response rate after induction was superior for conventional first-line therapy (58.5% vs 48%, P = 0.003) but at the end of treatment, the CR rate was not statistically different (52% vs 48%, P = 0.19). Conventional chemotherapy had a better five-year event-free survival than alternating regimen (33% (95% CI: 30-36%) vs 28% (95% CI: 26-30%), P = 0.0289) but overall survival was not statistically different (40% (CI 95% 38-42%) vs 36% (CI 95% 34-38%), P = 0.068). In this elderly high risk population, the toxicity was very high: 19% in arm A and 26% in arm B died during treatment.
  
  
  CONCLUSIONS
  Alternating regimen did not improve outcome, was less efficient and more toxic.
authors.affiliation: Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium. andre.bosly@sang.ucl.ac.be
authors.forename: A
authors.initials: A
authors.lastname: Bosly
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: G
authors.initials: G
authors.lastname: Fillet
authors.forename: R
authors.initials: R
authors.lastname: Herbrecht
authors.forename: M
authors.initials: M
authors.lastname: Divine
authors.forename: B
authors.initials: B
authors.lastname: Dupriez
authors.forename: C
authors.initials: C
authors.lastname: Nouvel
authors.forename: E
authors.initials: E
authors.lastname: Deconninck
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: P
authors.initials: P
authors.lastname: Gaulard
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D014751:Vindesine; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate